Vidac Pharma Granted Key Patent by USPTO

Vidac Pharma Holding Plc continues to garner attention following the grant of an important patent by the United States Patent and Trademark Office (USPTO). This patent solidifies Vidac Pharma's position in the oncology field, specifically regarding its innovative cancer treatment strategy that targets the altered metabolism of cancer cells, known as the Warburg effect.

This development is pivotal as Vidac Pharma holds exclusivity in the U.S. market for its unique approach. The products, such as VDA-1102 and VDA-1275, are designed to reverse abnormal cancer cell metabolism by preventing the binding of enzyme hexokinase-2 to mitochondrial VDAC channels, thus restoring normal cell function. These therapeutic candidates show potential in halting cancer cell growth and enhancing programmed cell death.

The positive momentum is supported by a recent capital injection of over EUR 0.6 million from investors, aimed at propelling clinical trials for these promising therapies. A key focus will be on the second phase 2b trial for VDA-1102 to combat advanced actinic keratosis and exploring its effectiveness against cutaneous T-cell lymphoma.